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Lethal Toxin 
and the Urokinase- Activated Anthrax Lethal Toxin 
 
ZEIN JEAN KASBO 
 
ABSTRACT  
 
In this study, we attempt to simultaneously target the major hallmarks of 
colorectal cancer (CRC), the MAPK pathway and the urokinase plasminogen activator 
system using a dual-selective, Urokinase-activated, recombinant anthrax lethal toxin 
(PrAgU2/LF). Colorectal cancer is the third most common cancer type in the world, and 
the second leading cause of death in the United States according to the American cancer 
society. Therefore, the need for alternative approaches is essential in order to overcome 
the difficulties faced with traditional therapies. PrAgU2/LF is composed of 2 
components the binding moiety PrAgU2 and the catalytic moiety LF. PrAgU2 was 
obtained by replacing the furin cleavage sequence on PrAg with a urokinase- specific 
cleavage sequence. LF is a metalloprotease that cleaves and inactivates MEKs and hence 
inhibits the MAPK pathway. We assessed the cytotoxic effects and mechanisms of 
PrAgU2/LF on a panel of 9 human colorectal cancer cell lines.PrAg/LF, PrAg/FP59 and 
 viii 
 
PrAgU2/FP59 were used as controls for the different components of this system. 
PrAgU2/LF was not significantly cytotoxic to any of the cell lines tested, which were 
also resistant to PrAg/LF, indicating resistance to the inhibition of the MAPK pathway. 
This was further confirmed by resistance of these cells to the MEK1/2 inhibitor U0126. 
Notably, the majority of cell lines showed high levels of phospho-MEK1/2 but, 
surprisingly, no phospho-ERK1/2. Furthermore, targeting both the MAPK pathway and 
the PI3-kinase/Akt pathway also failed to induce cytotoxicity in colon cancer cell lines. 
In order to assess the possibility of targeting the uPA/uPAR system alone, we 
determined expression levels of uPAR and tested the sensitivity of CRC cells to 
PrAgU2/FP59, a urokinase activated, MAPK-independent version of the toxin. The vast 
majority of cell lines tested expressed uPAR and were sensitive to PrAgU2/FP59, 
indicating the possibility for targeting this protease system in CRC.  
 
Keywords: CRC , Anthrax lethal toxin (PrAg/LF) , Urokinase system , MAPK, Dual-
targeting. 
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CHAPTER ONE 
 
INTRODUCTION 
1.1.Colorectal cancer (CRC) 
Colorectal cancer (CRC) is one of the most common types of cancer, being the 
third most prevalent type of tumor worldwide. Colorectal cancer, along with cancers of 
the lungs and prostate in men and of the lungs and breast in women, account for 
approximately 48% of cancer mortality worldwide. According to the American cancer 
society, colorectal cancer accounted for approximately 50,830 deaths in 2013 in the 
USA. A considerable decline in death rates due to colorectal cancer have been achieved 
recently due to advanced screening programs that lead to early detection and 
improvement in cancer diagnosis and therapy. Nevertheless not all demographic groups 
are able to benefit from these advances, partly because the decline in mortality is due to 
early detection and improvement of treatment, which are not readily available for all 
demographic groups (Siegel, 2013). A small proportion of colorectal cancer cases are 
genetically inherited while the vast majority of cases (90 to 95%) occur sporadically 
with the rates of CRC increasing with urbanization and industrialization. Etiology of the 
disease includes many factors such as smoking, prolonged use of non-steroidal anti-
inflammatory drugs and genetic predisposition (Labianca, 2010). 
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In general, colorectal cancer starts in the form of small, benign adenomatous 
polyps, some of which become cancerous with time. In the early stages of the disease, 
small polyp-induced symptoms range from “no symptoms to very few non-specific 
symptoms” such as change in bowel habits, abdominal pain, unexplained weight loss 
and constant fatigue. Advanced symptoms include severe tiredness, anemia, obstruction 
in the bowel and metastases to liver resulting in hepatomegaly and jaundice in addition 
to a host of other symptoms. For these reasons, colorectal cancer is generally diagnosed 
either as a result of screening or if a patient presents with symptoms (Labianca, 
2010).Diagnosis of CRC in usually carried out by endoscopy (colonoscopy) with a 
subsequent CT scan used to determine the extent of the tumor. Moreover, other imaging 
tests such as PET and MRI can be used. Once diagnosed, the next step is colorectal 
cancer staging, which is carried out in order to determine the degree of tumor 
penetration and the presence or absence of lymph nodes involvement using the TNM 
system. The TNM is a classification system that includes both the clinical and the 
pathological classification. However, the early diagnosis of peritoneal carcinomatosis 
using the various diagnostic tools currently available is still poor (Labianca, 2010). 
Surgery remains the only curative therapeutic approach for localized colorectal 
cancer. However, metastatic cancer, which spreads to distant organs and tissues, is 
usually not curable and treatment is then directed to extend the patients' lifespan and 
improve his quality of life mainly via chemotherapy and palliative care. During surgical 
interventions, the perioperative milieu seems to facilitate the progression of metastatic 
colorectal tumors due to the exposure to lipopolysaccharide (LPS) contaminants that 
enter the systemic circulation due to bacterial gut translocation. It has been shown that 
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LPS enhance expression and activation of the urokinase plasminogen activator system 
that plays a crucial role in cancer metastasis (Killeen, 2009). Advanced stages of 
metastatic cancer usually involves combination or multiagentchemotherapy regimen 
(McLeod, 2010). Until recently, CRC first-line treatment plans include: 5-fluorouracil 
(FU) which is routinely administered along with leucovorin (FU/LV), or with irinotecan 
(IFL or FOLFIRI). The most  common treatment plan includes the applicatoion of 5-
fluoruracil (5FU)/LV and oxaliplatin (FOLFOX4). However, Increased susceptibility to 
infection due to severe neutropenia is one important side effect of this regimens that has 
been shown in 41.1% of patients. Moreover, chemotherapy has been shown to elevate 
oxidative stress levels which results in DNA, proteins, and cellular membrane damage in 
addition to spreading out the neoplastic cells (Santandreu, 2011).Therefore, the need for 
novel, potent and tumor-selective approaches for the treatment of colorectal cancer has 
become essential in order to overcome the difficulties faced in traditional therapies. Such 
novel approaches include targeting tumorigenic signaling pathways, such as the 
mitogen-activated protein kinase (MAPK) pathway, and cell surface proteases such as 
the urokinase plasminogen activator system (uPA/uPAR). 
 
1.2.  The MAP Kinase signaling pathway 
 Mitogen-activated protein kinases (MAPK) are a family of serine/threonine 
kinases that control important cellular processes such as proliferation, differentiation, 
growth, migration and cell death. This is carried out mainly by controlling gene 
expression, in particular through regulation of transcription. The MAPK pathway is 
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activated by extracellular growth signals such as growth hormones, epidermal growth 
factors and many mitogenic stimuli (Yang, 2013). To date, there are four major MAPK 
modules in mammalian cells which are the extracellular signal-regulated kinase 1 and 2 
(ERK1/2) module, the extracellular signal-regulated kinase 5 (ERK 5) module, the 
stress-activated protein kinase 1 (JNK) module and the stress-activated protein kinase 2 
(P38 pathway) module. Each MAPK pathway is comprised of a three-tiered cascade in 
which a mitogen-activated protein kinase kinasekinase (MAPKKK) phosphorylates and 
activates a mitogen-activated protein kinase kinase (MAPKK) which in turn 
phosphorylates and activates a mitogen-activated protein kinase (MAPK). Activation of 
the MAPKs results in their nuclear localization where they can phosphorylate and 
regulate transcription of a wide array of genes involved in vital biological processes. 
Upstream of the Kinase modules are members of the Rho and Ras families of GTPases 
that relay signals from receptor complexes to the modules. A recent genome-wide 
association study carried out by Lascorz et al. (2010) evaluated the genetic variations 
observed in the MAPK pathway in association with cancer and identified the MAPK-
signaling pathway as one of the most important associated gene markers to several types 
of cancer including CRC. Hence, targeting the MAPK pathway is a tempting potential 
approach for the treatment of CRC. The association of mutations affecting the MAPK 
pathway and several types of tumors, including CRC is not surprising since we know 
that the different modules of the MAPK pathway are involved in fundamental cellular 
processes such as cell proliferation, differentiation and apoptosis, where abnormalities in 
MAPK signaling affect most if not all of these processes. Changes in the MAPK 
pathway may transform cells and enable them to acquire the critical capabilities of 
cancerous cells such as independence of proliferation signals, escape of apoptosis, 
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resistance to anti-mitotic signals, the capability to invade, metastasize and sustain 
angiogenesis. (Dhillon, 2007) The most frequent mitogenic mutations of MAPK 
pathway affect the Ras–Raf axis in the ERK pathway suggesting it functions as a 
regulatory hotspot of the MAPK pathway. 
In this context, the ERK pathway has attracted attention for drug discovery for 
the past 15 years by targeting Ras, Raf and MEK1/2 mainly. Hence, a main focus of 
research today is the development of MAPK inhibitors and the assessment of their 
efficacy and selectivity in cancer therapy. Moreover, it has been recently shown that 
targeting downstream effectors can result in increased specificity and decreased side 
effects by eliminating only the targeted functions, thus ERK inhibitors are currently 
being actively developed. Hence, novel inhibitors of the Ras-Raf-MEK1/2-ERK1/2 
branch of the MAPK pathway are urgently needed. A recently identified, and actively 
investigated, potent inhibitor of the MAPK pathway is anthrax lethal toxin (PrAg/LF).  
 
1.3. Anthrax Lethal Toxin 
Anthrax lethal toxin is produced by the gram-positive, spore-forming bacterium 
Bacillus anthracis, the causative agent of anthrax infections. Two major virulence 
factors are secreted by B. anthracis: the anthrax lethal toxin and the anthrax edema 
toxin. Anthrax toxin proteins are encoded on an extra chromosomal plasmid pXO1 (182 
kb). The toxin components are: the protective antigen (PrAg, 83 kDa), the lethal factor 
(LF, 89 kDa) and the edema factor (EF, 90 kDa). Each factor alone is non-toxic, 
however they combine to form the different anthrax toxins, where lethal toxin (LT) is 
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composed of a combination of PrAg and LF, whereas edema toxin (ET) is composed of 
a combination of PrAg and EF. Protective antigen (PrAg) functions as the binding and 
internalization moiety while lethal factor (LF) and edema factor (EF) function as the 
catalytic moieties. Lethal factor (LF) is a zinc-dependent metalloprotease that cleaves 
and inhibit the mitogen-activated protein kinase kinases (MEKs) 1, 2, 3, 4, 6 and 7 
resulting in the inactivation of the 3 major MAPK pathways: the extracellular-signal-
regulated kinase via MEK 1 and 2, the p38 pathway via MEK 3 and 6, and the Jun N-
terminus kinase (JNK) through MEK 4 and 7. Edema factor is a calmodulin-dependent 
adenylyl cyclase that leads to an increase in the intracellular levels of cAMP leading to 
variable responses such as tissue damage and death. Two anthrax toxins receptors were 
identified: The tumor endothelial marker 8 (TEM8) and the capillary morphogenesis 
gene-2 (CMG2) also referred to as anthrax toxin receptors 1 and 2, respectively. The 
physiological functions of the 2 receptors are not yet fully understood. However, studies 
have shown TEM8 up regulation in human colorectal cancer suggesting it to be a 
potential target for cancer therapy. Moreover, CMG2 was also suggested to have a role 
in angiogenesis (Liu, 2014). 
 
1.4. Anthrax lethal toxin mechanism of action  
Protective antigen (PrAg) binds to its membrane receptor on target cells (TEM8 
and CMG-2) and is proteolytically cleaved by ubiquitously-expressed furin-like 
proteases at a specific sequence 164RKKR167 generating the 63 kDa receptor-bound 
fragment PrAg63 and the 20 kDa free fragment PrAg20. Release of PrAg20 activates 
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PrAg63 which oligomeraizes (both the heptamer and octamer forms have been observed) 
allowing the binding of three to four molecules of LF. The PrAg63 oligomer/LF complex 
then undergoes clathrin-dependent receptor-mediated endocytosis (Liu, 2014). 
 
Figure 1.1 : Anthrax lethal toxin mode of action (Shihui Liu, MahtabMoayeri, and 
Stephen H. Leppla, 2014). Protective antigen (PrAg) binds to its membrane receptor on 
target cells (TEM8 and CMG-2) and is proteolytically cleaved by furin-like proteases at 
a specific sequence 164RKKR167 generating the PrAg63 activereceptor-bound fragment 
and the PrAg20 free fragment. PrAg63heptamerizes allowing the binding of three to four 
molecules of LF. The PrAg63 oligomer/LF complex then undergoes endocytosis. Upon 
acidification of late endosomes LF translocate into the cytosol. LF is a Zinc-
metalloprotease that cleaves and inactivates MEKs leading to the inhibition of MAPK 
pathways. 
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The translocation of LF from the endosome to the cytosol occurs following one 
of two mechanisms. In the first mechanism, considered by far as the most common, 
upon acidification of the late endosome, the PrAg63 pre-pore oligomer undergoes a 
conformational change leading to the formation of a channel through which LF escapes 
the endosome and translocates into the cytosol of the cell. In the second mechanism, LF 
may be translocated into the intraluminal vesicles in order to be transported to the 
endosome through multivesicular bodies. Once inside the endosome, back fusion of the 
intraluminal vesicles with the limiting membrane delivers LF to the cytosol. LF is a 
Zinc-metalloprotease that cleaves and inactivates MEKs leading to the inhibition of 
MAPK pathways (Liu, 2014). In this context, MAPK-dependent tumors could be 
selectively vulnerable to anthrax lethal toxins. Several studies have recently shown the 
potency and tumor-selectivity of recombinant anthrax lethal toxin in a number of 
MAPK-dependent tumor types both on cell lines and in animal models. An in vitro study 
by Koo et al. (2002) and by Abi-Habib et al. (2005) demonstrated potency, selectivity 
and mechanism of action of anthrax lethal toxin on melanoma cells (Abi-Habib. 2005). 
Moreover, an in vivo study was done by the same group in 2006 demonstrating the in 
vivo potency of the toxin and showing that systemic treatment of a human melanoma 
xenograft model with PrAg/LF  yielded complete tumor regression with minor 
cytotoxicity to mice, justifying further preclinical studies (Abi-Habib, 2006). Another 
study by huang et al. (2008) showed Fusion anthrax lethal toxin also exhibit a potential 
capability of inhibiting the MAPK pathways in renal cell carcinoma that have increased 
expression levels of both MKK1 and ERK2 and  resulting in cell death. In 2013, Kassab 
et al. demonstrated PrAg/LF has a significant cytotoxic effect on MAPK-dependent 
AML cells (Kassab, 2013). 
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1.5. The Urokinase Plasminogen Activator protease System (uPA  
System) 
Expression of the urokinase plasminogen activator protease (uPA/uPAR) system 
is one important hallmark of invasive and metastatic tumors. It is highly expressed in 
many types of solid and hematological malignancies and at the same time is rarely 
expressed on normal cells (Abi-Habib, 2006). Invasiveness and metastasis is considered 
a multi-step process that alters adhesion and physical movement of the cell. This 
requires the degradation of the basement membrane (BM) and the extracellular matrix 
(ECM), which carried out by specific cell surface proteases including Matrix 
metalloproteases (MMPs) and the urokinase plasminogen activator protease system 
(uPA/uPAR) (Lu, 2012). In colorectal cancer, excessive degradation of the ECM is 
attained via the matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 
(MMP-9), and urokinase-type plasminogen activator (uPA/uPAR) (Kim, 2006). Thus, 
the uPA/uPAR system expression is considered as a marker for malignancy and a bad 
prognostic marker in tumors including CRC. The urokinase plasminogen activator 
system is involved in the control of matrix integrity and cell signaling resulting in 
different responses, under physiological and/or pathological conditions.  
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Figure 1.2. Different effects of uPA system on cell signaling, proliferation and 
Extracellular matrix degradation (Daniela Alfano et al., 2005). The uPA system 
consists of the urokinase-type plasminogen activator (uPA), specific membrane receptor 
(uPAR), and the plasminogen activator inhibitors (PAIs). The inactive enzyme binds to 
the receptor and becomes activated upon cleavage by plasmin and conversion into the 
active uPA. Active uPA then converts the zymogen plasminogen to the active plasmin. 
plasmin in turn leads to the activation of matrix metalloproteases, leading to the massive 
degradation and loss of integrity of the extracellular matrix. And regulation of fibrin 
degradation hence clot lysis. Also release of VEGF, bFGF and TGF-β factors which 
have role in proliferation and wound healing processes. 
 
The uPA system consists of the urokinase-type plasminogen activator (uPA) and 
its own specific membrane receptor (uPAR), in addition to the plasminogen activator 
inhibitors (PAIs) (Tang, 2013). The urokinase plasminogen activator is secreted in the 
form of inactive enzyme (pro-uPA) and becomes activated following cleavage by 
plasmin and conversion into the active enzyme uPA. Active uPA then converts the 
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zymogen plasminogen to the active serine protease plasmin, starting a positive feedback 
loop and providing the cell with surface protease activity capable of proteolytic 
degradation of the extracellular matrix and of regulation of matrix integrity via the 
activation of pro-metalloproteinases (pro-MMPs) into active metalloproteases (MMPs) 
(Alfano, 2005). Hence, by leading to the activation of plasmin, the uPA/uPAR system 
starts a positive feedback loop allowing the generation of active plasmin, which, in turn, 
leads to the activation of matrix metalloproteases, leading to the massive degradation 
and loss of integrity of the extracellular matrix, a pre-requisite for cancer invasion and 
metastasis. uPA receptor (uPA-R) is a 50-65-kD glycosylphosphatidylinositol (GPI)-
anchored protein. uPAR binds to both inactive pro-uPA and active uPA, binding of uPA 
to uPAR stabilizes the molecule and protects it from inhibition by plasminogen activator 
inhibitors (PAIs), consequently leading to more plasminogen being converted to active 
plasmin. In the absence of uPAR, active uPA is rapidly inhibited by PAIs, hence the 
need for the presence of both components uPA and uPAR to achieve an active urokinase 
plasminogen activator system. The glycoproteins plasminogen activator inhibitors (PAI 
1 and PAI 2) regulate the uPA system. They inhibit both free and receptor-bound uPA, 
with the inhibition constant for receptor bound uPAR being several hundred folds higher 
(Kim, 2006). Under normal conditions, plasma and tissue concentrations of PAIs are 
very low. However, their levels increase under pathological conditions. PAI-1 plays an 
important role in the recycling of the urokinase system components. PAI-1 binds to 
uPA/uPAR resulting in the formation of a (uPA-R/uPA/ PAI-1) complex. The complex 
then undergoes internalization and breaks down into 2 fractions, the uPA/PAI-1 and 
uPA-R. The uPA/PAI-1 complex is degraded in the lysosome while the uPA receptor is 
recycled to the cell surface. 
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Studies have shown that increased levels of PAI-1 are associated with metastatic 
cancers in comparison with non-metastatic cancers. Thus, PAI 1 along with uPA, are 
considered poor prognostic markers ( Kim, 2006). The uPA system, as noted previously, 
is not normally expressed under physiological conditions, except during particular 
processes such as wound healing or tissue remodeling (Andreasen, 2000). A study by 
Tae-Dong Kim in 2006 showed that colorectal cancer tissues have significantly higher 
levels of uPA and PAI-1 when compared to corresponding normal mucosal tissues. High 
levels of uPA and uPAR were observed in 100% (22/22) of patient colorectal tissues 
(Kim, 2006). Considering all these facts, the uPA system was and still is of great interest 
as a selective, potential marker of cancer cells with minimal expression on normal 
healthy cells. One study in 2004 by Abi-Habib et al., attempted to take advantage of the 
overexpression of uPA/uPAR on AML cells to generate a urokinase-activated, dual-
specific fusion toxin, DTU2GMCSF. This toxin consists of the catalytic and 
translocation domains of diphtheria toxin (DT) and the granulocyte macrophage colony-
stimulating factor (GMC-SF). The furin cleavage site on diphtheria toxin was replaced 
by a uPA cleavage site termed U2 in order to enhance specificity to uPA/uPAR 
expressing AML cells. The single targeting moiety using DT388GMCSF showed clinical 
efficacy but also showed cross-reactivity with GMCSF-expressing normal cells. 
However, DTU2GMCSF, the modified, urokinase-activated fusion toxin with dual 
specificity exhibited a significantly increased specificity and reduced normal cells 
toxicity while retaining potency and range (Abi-Habib, 2004). 
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1.6. The dual- selective recombinant toxin PrAgU2/LF 
In PrAgU2, the furin cleavage site of PrAg (164RKKR167) has been replaced by a 
urokinase-specific cleavage site termed U2 (163PGSGRSA169). By this modification, the 
new engineered fusion toxin theoretically should bind to all cells through the anthrax 
toxin receptors; however, it will get activated only on tumor-cells expressing an active 
uPA/uPAR system. Upon binding and activation by urokinase, the toxin complex would 
undergo endocytosis and eventually release LF into the cytosol. Once in the cytosol, LF 
inactivates MEKs and hence the MAPK pathways leading to proliferation inhibition and 
rapid cell death in MAPK-dependent cancer cells. 
 
1.7.Targeted fusion protein toxins: 
Recombinant anthrax lethal toxin (PrAg/LF) and its urokinase-activated version 
(PrAgU2/LF) belong to the category of targeted cancer therapeutics, and more 
specifically to the category of fusion toxins. Fusion Toxins are recombinant proteins that 
are genetically modified to specifically target tumor cells. These targeted toxins are 
composed of a targeting polypeptide ligand associated with a bacterial or plant toxin. 
Fusion toxins represent a novel class of tumor-specific therapeutics that aim to both 
enhance malignant cell specificity and minimize undesirable cytotoxicity to normal 
cells. A number of these genetically modified fusion toxins have been developed under 
good manufacturing practice and reached clinical trials. Despite the multiple hurdles of 
working with such a complex molecules, promising results were obtained to date 
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(Frankel.2000). The fusion toxin may target a tumor specific cell receptor or marker and 
the toxin moiety would enter the cell and induce cell death such in the case of 
DTGMCSF (Diphtheria toxin granulocyte-macrophage colony-stimulating factor) and 
DT388IL3 (Diphtheria toxin interleukin 3), among others. These two recombinant toxins 
target the GMCSF receptors and IL3 receptors, respectively on leukemic cells (Frankel, 
2008) (Abi-Habib, 2004) while the toxin moiety (DT) results in cell death by inhibiting 
protein synthesis. On the other hand, the fusion toxin may target specific pathways that 
are up-regulated in tumor tissues via the toxin moiety such as Anthrax lethal toxin 
(PrAg/LF). In this case, PrAg, the binding and internalization moiety binds to the 
anthrax lethal toxin receptors 1 & 2 and mediates internalization of lethal factor LF 
which will inhibit the MAPK pathway, a major hallmark of tumor cells. This inhibition 
will results in cell cycle arrest and cell death (depending on the tumor type) leading to 
tumor regression (Kassab, 2013). 
Recently, a new category of recombinant toxins with dual-targeting capabilities 
have been developed such as DTU2GMCSF, where, in addition to targeting the GMCSF 
receptors it targets the urokinase plasminogen activator (uPA) system which is a tumor-
specific protease. Therefore, enhanced tumor specificity and less normal tissue damage 
can be obtained (Abi-Habib, 2004).PrAgU2/LF is another dual selective-tumor fusion 
protein toxin. It targets MAPK dependent tumor cells that are at the same time express 
the tumor-specific urokinase plasminogen activator proteases. PrAgU2/LF induces the 
inhibition of MAPK pathways and results in inhibition of cell proliferation and 
apoptosis.Hence, in this study, we attempt to target the two major hallmarks of 
colorectal cancer, the MAPK pathway and the urokinase plasminogen activator system 
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by modifying the furin-activation site of PrAg into a urokinase-activation site termed 
U2. Hence, the resulting toxin PrAgU2/LF is a dual-specificity, urokinase-activated 
recombinant anthrax lethal toxin, which would require expression of uPA/uPAR and 
dependence on the MAPK pathway for activity.  
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CHAPTER TWO 
MATERIALS AND METHODS 
 
2.1. Expression and purification of PrAg, LF and FP59 
Recombinant anthrax proteins, PrAg (activated by furin), PrAgU2 (activated by 
the urokinase plasminogen activator), LF and FP59 (fusion of the PrAg binding domain 
of LF and the catalytic domain of Pseudomonas aeruginosa exotoxin A, which inhibits 
protein synthesis and induces MAPK-independent cell death), were expressed and 
purified in the laboratory of Stephen H. Leppla at the National Institute of Allergies and 
Infectious Diseases (NIAID) of the National Institutes of Health (NIH) in Bethesda, 
MD, as described previously (Ramirez DM, 2002) (Liu S, 2001). Briefly, fermentation 
was carried out by inoculating a 12 to 14 h old starter culture grown from a frozen stock. 
Three to ten liter fermentations were carried out controlling dissolved oxygen (DO) at 
30% saturation, temperature at 37
o
C, and pH at 7.5. At harvest time, 5 mM EDTA and 
10 ug/ml PMSF (phenylmethylsulfonyl fluoride) were added to the culture. Purification 
was then carried out as follows: 1. Packed-bed hydrophobic interaction chromatography 
during which the cell suspension was centrifuged and the supernatant was passed 
through a 0.2 -µm hollow fiber filter (AGT, Needham, MA). The filtered broth was then 
concentrated 20 fold using a 10K membrane. After sample loading, the column was 
washed with 10 column volumes (CV) of equilibration buffer and rPA was eluted with a 
30 CV linear gradient of (NH4)2SO4 in 10 mM HEPES, 5 mM EDTA. The rPA-
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containing fractions were pooled for further purification. 2-Expanded-bed hydrophobic 
interaction chromatography in which the cell suspension was diluted 1:1 with buffer and 
the diluted cell suspension was loaded upward at 300 cm/ h. The column was washed in 
expanded mode with 10 CV of equilibration buffer. Elution was performed in packed-
bed mode with 8 CV of elution buffer at 100 cm/ h. 3- Anion exchange chromatography 
in which fractions from HIC were dialyzed against 20 mMTris pH= 8.9/ 5 mM EDTA 
and loaded on a Q Sepharose Fast Flow (Amersham Pharmacia Biotech) column. The 
protein was eluted using a 20 CV linear gradient of NaCl in the same buffer. rPA-
containing fractions were concentrated and dialyzed against PBS. (Ramirez DM, 2002) 
(Liu S, 2001). LY294002 (PI3K inhibitor) was purchased from Cell signaling 
Technology (Danvers, MA). U0126 (MEK1/2 inhibitor) was purchased from Cell 
signaling Technology (Danvers, MA).  
 
2.2. Cells and cell lines 
Nine human Colorectal cancer cell lines SW1116, SW837, SW948, LoVo, Caco-
2, HT-92, T-84, Sk-co1 and SNU-c1 were obtained from the American Type Culture 
Collection (ATCC) and grown in DMEM medium supplemented with 10% heat-
inactivated fetal bovine serum and 1% penicillin/streptomycin. Cells were maintained in 
a water-jacketed CO2 incubator at 37
o
 C, 5% CO2.  
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2.3. Proliferation inhibition assay (Cytotoxicity) 
Sensitivity of CRC cell lines to PrAg/LF and PrAgU2/LF was determined using 
a proliferation inhibition assay as described previously (Abi-Habib RJ, 2005) We have 
also used a recombinant protein, termed FP59, consisting of the PrAg binding domain of 
LF fused to the catalytic domain of Pseudomonas aeruginosa exotoxin A. Binding of 
FP59 to PrAg or PrAgU2 and its translocation into the cytosol are identical to those of 
LF, however, it does not target the MAPK pathway but rather ADP-ribosylates 
elongation factor 2 (EF-2) leading to inhibition of protein synthesis and cell death. 
Hence, FP59 is a MAPK-independent targeting moiety. PrAg/FP59 was used as a 
control for catalytic domain entry into the cytosol of CRC cells, whereas PrAgU2/FP59 
was used as a control for the cell surface activity of the urokinase plasminogen activator 
independently of cell sensitivity to the inhibition of MAPK pathways Briefly, aliquots of 
10
4
 cells/well, in 100 µl cell culture medium, containing a fixed concentration of 10
-9
 M 
LF or FP59, were plated in a flat-bottom 96-well plate (Corning Inc. Corning, NY). 
Then, 50 µl PrAg or PrAgU2 in media were added to each well to yield concentrations 
ranging from 10
-8
 to 10
-13
 M. Following a 48 h incubation at 37oC/5% CO2, 50 µl of 
XTT cell proliferation reagent (Roche, Basel, Switzerland) were added to each well and 
the plates incubated for another 4 h. Absorbance was then read at 450 nm using a 
microplate reader (Thermo Fisher Scientific, Waltham, MA). Nominal absorbance and 
percent maximal absorbance were plotted against the log of concentration and a non-
linear regression with a variable slope sigmoidal dose-response curve was generated 
along with IC50 using GraphPad Prism 5 software (GraphPad Software, San Diego, CA). 
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All assays were performed at least twice with an inter-assay range of 30% or less for 
IC50.    
 
2.4. Cell cycle analysis 
The impact of treatment on the cell cycle of CRC cells was determined using 
Propidium Iodide (PI)-staining on flow cytometry. Briefly, cells incubated with PrAg/LF 
(10,000 pM), PrAg/FP59 and LF alone as a control in a 6-well plates (Corning Inc. 
Corning, NY) for 48 and 72 h at 37oC, 5% CO2, were harvested and fixed in 70% 
ethanol for a minimum of 24 h, at -20
o
C. Cells were then incubated in 500 µl PI staining 
solution (50 µg/ml) for 40 min at 37
o
C. Samples were then read on a C6 flow cytometer 
(BD Accuri, Ann Arbor, MI) and total cell DNA content was measured on FL2-A. 
Percent of cells in G0/G1, S and G2/M phase was determined in control cells and in cells 
treated with PrAg/LF and with PrAg/FP59 following gating for the cell population on 
width versus forward scatter.  
 
2.5. Inhibition Assays  
CRC cells were incubated with either the small molecular weight PI3 kinase 
(PI3K) inhibitor LY294002 (Cell Signaling Technology, Danvers, MA) alone and in 
combination with PrAg/LF or with the small molecular weight MEK1/2 inhibitor U0126 
(Cell Signaling Technology, Danvers, MA). Briefly, 10
4
 cells/well were plated in 100 µl 
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of medium in a flat-bottom, 96-well plate. Then 100 µl of either medium (control cells) 
or medium containing LeTx (10
-8
M PrAg/10
-9
M LF), LY294002, U0126 or a 
combination of the above were added. When LY294002 or U0126 were used, they were 
added as described above for PrAg or PrAgU2 but in concentrations ranging from 10
-4
 to 
10
-9
 M. Cells were then incubated for 48 h at 37oC, 5% CO2 followed by the addition of 
50 µl of XTT cell proliferation reagent (Roche, Basel, Switzerland). Cells were 
incubated for another 4 h and absorbance was read at 450 nm using a 96-well plate 
reader (Thermo Fisher Scientific, Waltham, MA). Data was analyzed using GraphPad 
Prism V software (GraphPad Software, San Diego, CA). The absorbance and the percent 
absorbance of controls were compared between the different treatment groups.   
 
2.6. Intracellular Staining and Flow Cytometry Analysis  
Active MEK1/2, ERK1/2 and AKT in untreated CRC cell lines was assessed by 
determining the presence or absence of phosphorylated form of each of MEK1/2, 
ERK1/2 and AKT  using flow cytometry as described previously. Approximately 3x10
6
 
cells were fixed in 70% ethanol for 15 min. cells were resuspended in antibody binding 
buffer containing 0.05% Triton-X 100, and incubated with a 5µl of anti-phospho-
ERK1/2 (Ser 217/221) rabbit monoclonal antibodies (Cell Signaling Technology, 
Danvers, MA) or anti-phospho-MEK1/2  or  anti-phospho-AKT,  for 1 h at 37
o
C, 
followed by a 30-minute incubation with a 1/100 dilution of a FITC-conjugated mouse 
anti-rabbit polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA). Fixed cells 
stained only with FITC-conjugated mouse anti-rabbit polyclonal antibody were used as 
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isotypic control.  Samples were then analyzed using a C6 flow cytometer (BD Accuri, 
Ann Arbor, MI).  The presence of p-ERK1/2, p-MEK1/2, p-AKT was analyzed and 
compared with that of the isotopic control. Positivity for the presence of p-ERK1/2, p-
MEK1/2 or p-AKT was determined using the ratio of fluorescence intensity (RFI) 
between the mean fluorescence intensity (MFI) of the stained cells and the MFI of the 
isotypic control. RFI > 2 was considered positive, RFI between 1.5 and 2 were 
considered slightly positive and RFI <1.5 was considered negative. 
 
2.7. Expression of uPAR 
Expression of the urokinase plasminogen activator receptor (uPAR) on CRC cell 
lines was determined using single cell staining with a FITC-conjugated anti-uPAR 
antibody on flow cytometry as described previously. Approximately 10
6
 cells were 
incubated with a 1/100 dilution of a FITC-conjugated anti-uPAR mouse monoclonal 
antibody (Cell Signaling Technology, Danvers, MA) in antibody binding buffer for 1 h 
at 37oC. Cells stained only with a FITC-conjugated mouse IgG were used as isotypic 
control. Samples were then analyzed using a C6 flow cytometer (BD Accuri, Ann Arbor, 
MI). The expression of uPAR was analyzed on FL1-H and compared with that of the 
isotopic control. Positivity for the presence of uPAR was determined using the ratio of 
fluorescence intensity (RFI) between the mean fluorescence intensity (MFI) of the uPAR 
stained cells and the MFI of the isotypic control. RFI > 2 was considered positive. RFI 
between 1.5 and 2 were considered slightly positive and RFI <1.5 was considered 
negative. 
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CHAPTER THREE 
 
RESULTS 
3.1. CRC cell sensitivity to PrAg/LF and PrAgU2/LF 
A panel of nine human CRC cell lines was tested for sensitivity to the 
recombinant anthrax lethal toxin PrAg/LF and its urokinase-activated version 
PrAgU2/LF. Cell viability following treatment was assessed using XTT proliferation 
inhibition assay which detects metabolically active cells after incubation with the toxin. 
PrAg/LF is activated by furin-like proteases and induces cell death via the inhibition of 
the MAPK pathway, whereas PrAgU2/LF is activated by the urokinase plasminogen 
activator system and also target the MAPK pathway. Only 1 of 9 cell lines tested (SNU-
c1) was sensitive to PrAg/LF with none being sensitive to PrAgU2/LF (IC50 >10,000 
pM) (Figure 3.1).To understand whether the resistance to PrAg/LF and PrAgU2/LF was 
due to cell resistance to the LF-mediated inactivation of MAPK pathway or due to the 
absence of  anthrax toxin receptors, we tested potency of PrAg/FP59 as a control. FP59 
is a fusion protein consisting of the PrAg binding domain of LF and the catalytic domain 
of Pseudomonas aeruginosa exotoxin A. Binding of FP59 to PrAg leads to FP59 
translocation into the cytosol just like LF, however, FP59 does not target the MAPK 
pathway but instead ADP-ribosylates elongation factor 2 leading to the inhibition of 
protein synthesis and cell death. FP59, therefore, is toxic to all cells once translocated 
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into the cytosol. Thus, PrAg/FP59 serves as a control for the presence or absence of 
anthrax toxin receptors and, in more general terms, the ability of the catalytic moiety to 
access the cytosol. As illustrated in Table 3.1 and Figure 3.1, 4 out of the 9 cell lines 
tested were not sensitive to PrAg/FP59 (HT-29, SW837, CaCo-2 and SW116), 
indicating that resistance to PrA/LF and, subsequently, to PrAgU2/LF of these cell lines 
is due to absence of anthrax toxin receptors and inability to internalize LF. The 
remaining 5 cell lines, were sensitive to PrAg/FP59, hence the resistance of 4 of them to 
PrAg/LF and PrAgU2/LF (T84, LoVo, Sk-Co-1 and SW948) was due to their resistance 
to the LF-mediated inhibition of the MAPK pathway (Table 3.1).  
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Figure 3.1. Sensitivity of human CRC cell lines to PrAg/LF, PrAgU2/LF and 
PrAg/FP59determined by a proliferation inhibition assay. Only one cell line, SNU-
c1(e) is sensitive to the treatment with PrAg/LF, whereas all the other 8 cell lines were 
not sensitive (a,b,c,d,f, g and i). None of the cell lines is sensitive to PrAgU2/LF (a, b, c, 
d, e, f, g and i). SW948(a), T-84(b), LoVo (d) and SNU-c1(e) are sensitive to 
PrAg/FP59. X-axis, log of the molar drug concentration, Y-axis, cell viability. 
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Table 3.1. Sensitivity of human CRC cell lines to PrAg/LF, PrAgU2/LF and 
PrAg/FP59.  
Cell line PrAg/LF  
(IC50,  pmol/L) 
PrAgU2/LF  
(IC50, pmol/L) 
PrAg/FP59  
(IC50, pmol/L) 
SNU-c1 71 8060 15 
T84 3950 >10000 6.0 
LoVo 1641 >10000 101 
Sk-Co-1 8120 >10000 222 
SW948 3041 3478 N/A 
HT-29 >10000 >10000 >10000 
SW837 >10000 >10000 >10000 
Caco-2 >10000 >10000 >1000 
SW1116 >10000 >10000 >10000 
 
N/A: Not available  
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Since cells that are resistant to PrAg/FP59 have no anthrax toxin receptors and thus, 
were unable to translocate LF into the cytosol, we needed an alternative method to test 
for their sensitivity to the inhibition of the MAPK pathway. For this purpose, we tested 
sensitivity of cells to the specific MEK1/2 small molecular weight inhibitor U0126. 
None of the CRC cell lines tested was sensitive to the U0126-mediated inhibition of the 
MAPK pathway further confirming the resistance of this tumor type to the targeted 
inhibition of MEKs (Figure 3.2). 
 
Figure 3. 2. Effect of MAPK pathway inhibition using the MEK 1/2 inhibitor U0126 
on CRC cell lines. None of the tested CRC cell lines showed sensitivity to the U0126-
mediated inhibition. 
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3.2. Cell cycle effect of PrAg/LF 
After assessing cytotoxicity of MAPK inhibition to CRC cell lines, we wanted to 
assess the effects of the inhibition of this pathway on the cell cycle of CRC cells and 
whether PrAg/LF has any cytostatic effect in this tumor type. Cell cycle analysis was 
carried out in the same panel of 9 cell lines following 48 and 72 hours of incubation with 
the highest concentration of PrAg/LF used. There was no difference in cell cycle status 
between control cells and cells treated with PrAg/LF for the majority of cell lines at any 
time point. However, cell cycle arrest at the G0/G1 phase was seen in 2 cell lines, the 
HT-29 and SW948 following treatment with PrAg/LF at both 48 and 72 hours of 
incubation (Figure 3.3). In the HT-29 cell line, the fraction of G0/G1 phase increased by 
23.7% following treatment with a corresponding decrease in the fraction of cells in the 
G2/M and S phases. This shows that the HT-29 cell line may express very low levels of 
anthrax toxin receptors allowing entry of LF to an extent that causes cell cycle arrest 
rather than cytotoxicity. Also in the SW948 cell line, the fraction of G0/G1 phase 
increased by 11.2 % following treatment accompanied by a corresponding decrease in 
the fraction of cells in G2/M and S phases (Figure 3.3). These results indicate that the 
LF-mediated inhibition of the MAPK pathway has limited cytostatic effects in CRC cell 
lines. This also further confirms the resistance of CRC cell line to the inhibition of 
MAPK pathway via PrAg/LF. 
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Figure 3.3. Cell cycle analysis of human CRC cell lines following treatment with 
PrAg/LF. Left panel represent control cells and right panel represent cells treated with 
10
4
pM for 48 hrs. Cells are gated on width versus forward scatter (R1/R2). Cells in 
G0/G1 are gated M1, G2/M are gated M2 and pre-G0/G1 (dead) are gated M3. No cell 
cycle arrest was shown in most cell lines, Caco-2 (a), LoVo (b), SW1116 (c) upon 
treatment with PrAg/LF for 48 hrs. A Small portion of cells exhibited cell cycle arrest at 
G0/G1 phase in HT-29 (d) and SW948 (e). 
 
d) 
e) 
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3.3. Analysis of MAPK activation  
In order to understand the underlying mechanisms of the resistance of CRC cells 
to the inhibition of the MAPK pathway, we investigated the activation level of this 
pathway in CRC cell lines by determining the phosphorylation levels of its ERK1/2 and 
MEK1/2 components using the intracellular staining technique on flow cytometry. We 
chose to focus on the ERK1/2 branch of the pathway because in previous studies we had 
demonstrated that the cytotoxic effects of LF were mediated through the inhibition of 
this branch of the Pathway. The majority of cell lines were either positive or slightly 
positive for the presence of phosphorylated MEK1/2 except For HT-29, SW948 and T-
84, which were clearly negative for phospho-MEK1/2. Remarkably, no phosphorylated 
ERK1/2 was detected in any of the CRC cell lines tested except in a relatively small 
proportion of cells of CaCo-2 and SK-Co-1, not involving more than 20% of the total 
cell population (Figure 3.4) (Table 3.2). This indicates that the MAPK pathway is not 
fully active in our CRC cell lines panel, and hence its inhibition using the fusion toxin 
PrAg/LF or the MEK1/2 specific-inhibitor would not affect cell proliferation or cell 
viability. It also indicates that phospho-ERK1/2 is the most important indicator of the 
activation of the MAPK pathway and subsequent sensitivity to its inhibition. This is in 
line with our findings in other tumor types including AML, in which sensitivity to the 
LF-mediated inhibition of the MAPK pathway depended on phosphor-ERK1/2 levels. 
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Figure 3.4. Analysis of MAPK activation. Intracellular staining of p-MEK1/2 and 
p-ERK1/2 through flow cytometry. High levels of active p-MEK were associated with 
the absence or very low levels of p-ERK in all tested CRC cell lines. Level of activation 
was determined according to the ratio of fluorescence intensity (RFI) of cells stained for 
phospho-MEK 1/2 or phospho-ERK1/2 (red) and cells incubated with the isotype control 
(black)., RFI> 2 was considered positive, RFI> 1.5 was considered slightly positive and 
RFI <1.5 was considered negative. 
  
g) 
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3.4.  Inhibition of PI3K pathway 
To determine whether CRC cell lines that are resistant to the inhibition of MAPK 
pathway could be sensitive to the inhibition of the PI3K/Akt pathway or whether a 
synergistic effect can be achieved by simultaneously inhibiting both the MAPK and 
PI3K pathways. We tested the sensitivity of a subset of CRC cell lines (SW837, T84, 
SK-Co-1 and SW1116) to the small molecular weight PI3K inhibitor LY294002, alone 
and in combination with PrAg/LF. None of the CRC cell lines tested were sensitive to 
LY294002, except SW837 which showed limited sensitivity to the inhibition of the 
PI3K/Akt pathway with an IC50 of approximately 11 micromolar (Figure 3.5). In 
addition, no additive effects were observed when LY294002 was used in combination 
with PrAg/LF, indicating resistance of the majority of CRC cell lines to the concomitant 
inhibition of both the MAPK and PI3K/Akt pathways (Figure 3.5). 
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Figure 3.5. Sensitivity of cell lines to the inhibition of PI3K pathway through 
LY294002.None of the tested CRC cell lines were sensitive to LY294002, except 
SW837 which showed limited sensitivity to LY294002 with an IC50 of approximately 
11 micromolar. Also, no additive effects were observed when using a combination of 
LY294002 andPrAg/LF.  
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3.5. Analysis of PI3K pathway activation 
In order to investigate the underlying molecular mechanisms of the resistance of 
CRC cells to the inhibition of the PI3K/Akt pathway, we determined the activation level 
of this pathway in CRC cell lines by determining the phosphorylation levels of its AKT 
components using intracellular staining on flow cytometry. None of the cell lines tested 
were positive for p-AKT (Figure 3.6) indicating the lack of activation of this pathway in 
CRC. This also explains the resistance of CRC cell lines to the inhibition of PI3K 
pathway using the specific inhibitor LY294002. The fact that the PI3K pathway is not 
active in the CRC cell line panel corresponds to the fact that its inhibition does not affect 
cell viability (Figure 3.6). 
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Figure 3.6. Activation status of PI3K pathway measured by level of p-AKT using 
intracellular staining on flow cytometry. The left panels represent cells stained with 
isotopic control and the right panels cells stained with anti phospho-Akt antibody. Cells 
were gated on width versus forward scatter. Positivity was determined by RFI which 
was  less than 1.5 for all the cell lines indicating no p-AKT found, hence PI3K pathway 
is not active. 
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3.6. Cytotoxicity of PrAgU2/FP59 
In order to assess the possibility of targeting the uPA/uPAR protease system 
alone, independently of the MAPK pathway, we tested the sensitivity of CRC cells to 
PrAgU2/FP59, a urokinase activated, MAPK-independent version of the toxin (Figure 
3.7). As expected, the 4 cell lines that did not express anthrax toxin receptors were not 
sensitive to PrAgU2/FP59 due to their inability to bind the toxin. However, out of the 5 
remaining cell lines that did express anthrax toxin receptors, 4 were sensitive to the 
urokinase-activated PrAgU2/FP59 (SNU-c1, T84, LoVo and SK-Co-1) with IC50 values 
ranging from 98 to 930 pM (Table 3.2, Figure 3.7). These results demonstrate the 
possibility of targeting the urokinase plasminogen activator protease system in CRC cell 
lines independently from targeting MAPK pathway.  
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Figure 3.7 . Cytotoxic effect of PrAgU2/FP59 on CRC cell lines.4cell lines were 
sensitive to the urokinase-activated PrAgU2/FP59 (SNU-c1, T84, LoVo and SK-Co-1) 
with IC50 values ranging from 98 to 930 pM. While 4 cell lines (HT-29. SW837, Caco-2 
and SW1116) were not sensitive to PrAgU2/FP59 as they were not expressing anthrax 
toxin receptors and thus cannot bind the toxin.  
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3.7. uPAR expression  
In order to determine the underlying mechanisms of the cytotoxicity of PrAgU2/FP59 to 
CRC cells, we assessed the expression levels of the urokinase plasminogen activator 
receptor (uPAR) through cell surface staining on flow cytometry. Positive uPAR 
expression was revealed by a ratio of fluorescence intensity of 2-folds or more for the 
uPAR stained cells in comparison to isotopic control cells. RFI between 1.5 and 2.00 
was considered slightly positive to the uPAR expression, while RFI <1.5 was considered 
negative. All but two of the cell lines tested exhibited high levels of uPAR expression 
with a ratio of fluorescence intensity (RFI) ranging from 2.33 to 17.02. The 2 remaining 
cell lines were slightly positive (SW837, RFI = 1.59) and negative (SW1116, RFI = 
1.16) for the expression of uPAR (Figure 3.8, Table 3.2). Results indicate a strong 
correlation between the uPAR expression and sensitivity to targeting the urokinase 
plasminogen activator system in CRC cells using PrAgU2/FP59. This demonstrates that 
CRC cell lines, for the most part, express high levels of uPAR rendering this prognostic 
marker a potential target for therapy of CRC. 
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Figure 3.8. uPAR expression in CRC cell lines.SW1116 was considered negative for 
the expression of uPAR with RFI = 1.16, SW837 was considered slightly positive with 
RFI = 1.59. all the other cell lines exhibited high levels of uPAR expression with a ratio 
of fluorescence intensity (RFI) ranging from 2.33 to 17.02.   
 
RFI = 2.33 
RFI = 2.87 
RFI = 17.02 
RFI = 1.16 
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Table 3.2.  Sensitivity of CRC cell lines to PrAg/LF and PrAg/FP59 and levels of 
MAPK activation represented by phospho-MEK 1/2 and phospho-ERK 1/2  levels, 
In addition to their expression of uPA receptors. 
 
Cell line PrAg/LF 
(IC50,  pmol/L)
#
 
Phospho-
MEK1/2 
(RFI) 
Phospho-
ERK1/2 
(RFI) 
PrAgU2/FP59 
(IC50, pmol/L) 
uPAR 
(RFI)
*
 
SNU-c1 71 NA NA 930 N/A 
T84 3950 1.12 (-) 1.33 (-) 146 3.59 (+) 
LoVo 1641 1.56 (+/-) 1.21 (-) 98 2.87 (+) 
Sk-Co-1 8120 2.27 (+) 1.24 (-) NA 17.02 
(+) 
SW948 3041 1.45 (-) 0.92 (-) 3449 N/A 
HT-29 >10000 1.37 (-) 1.48 (-) >10000 2.33 (+) 
SW837 >10000 2.14 (+) 1.13 (-) >10000 1.59 (+/-
) 
Caco-2 >10000 2.81 (+) 1.17 (-) >10000 5.73 (+) 
SW1116 >10000 1.69 (+) 0.96 (-) >10000 1.16 (-) 
 
N/A: Not available. 
* 
The (+) and (-) signs indicate positive and negative RFI for uPAR 
expression, respectively. 
# 
Same data as the one presented in the second column of Table 3.1. 
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CHAPTER FOUR 
 
DISCUSSION 
Oncogenic mutations in the Mitogen-activated protein kinase pathway have been 
identified as one of the most strongly associated gene markers to colorectal cancer CRC, 
especially mutations in the RAs–RAf–MEK1/2–ERK1/2 pathway which have been 
found in around 20-25 % of all human cancers. This suggests that the Ras–RAf–
MEK1/2–ERK1/2 axis is crucial for survival of this tumor. Moreover, studies have 
shown that CRC tissues have excessive expression of the Urokinase Plasminogen 
Activator protease system which is one important hallmark of invasive and metastatic 
cancer. In this view, we attempted in our study to target these 2 major hallmarks of 
CRC, the MAPK pathway and the uPA/uPAR system using the dual-selective 
Urokinase-activated,  recombinant anthrax lethal toxin PrAgU2/LF in comparison to the 
single targeting moiety (Recombinant anthrax lethal toxin - PrAg/LF ). The recombinant 
anthrax lethal toxin (PrAg/LF) is a targeted protein therapeutic that would bind to all 
cells and get activated upon cleavage by furin and lead to the translocation of LF into the 
cytosol. Once in the cytosol, LF inhibits all branches of the MAPK pathway via 
cleavage and inactivation of MEKs, and thus it has been of a great interest for tumor-
selective cancer therapy. On the other hand , our main interest was to test the Urokinase-
activated, recombinant anthrax lethal toxin PrAgU2/LF which is a dual-selective fusion 
toxin where the binding moiety can only be activated upon binding to uPA expressing 
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cells, and leading then to LF translocation into the cytosol where it inhibits the MAPK 
pathway resulting in cell death. 
A panel of 9 human CRC cell lines was employed in this study. Most of them are 
K-Ras mutants and therefore, we hypothesized would be dependent on the MAPK 
pathway for survival. PrAg/LF showed no cytotoxic effect on all but one of the 9 CRC 
cell lines tested. This was very surprising given the fact that the majority of cell lines 
were k-Ras mutant and were expected to have an active MAPK pathway. Therefore, and 
as expected, none of the cell lines were sensitive to the urokinase-activated PrAgU2/LF. 
Resistance to the PrAg/LF and PrAgU2/LF can be explained either by the absence of 
anthrax lethal toxin receptors or by these cells being MAPK-independent for survival. 
Thus, we used PrAg/FP59 fusion toxin as a control to test for presence or absence of the 
anthrax lethal toxin receptors. PrAg/FP59 is a recombinant protein composed of the 
PrAg binding domain of LF fused to the catalytic domain of Pseudomonas aeruginosa 
exotoxin A. Binding of FP59 to PrAg and its translocation into the cytosol are identical 
to those of LF, however, it does not target the MAPK pathway but rather ADP-
ribosylates elongation factor 2 leading to inhibition of protein synthesis and cell death. 
Five Cell lines were sensitive to PrAg/FP59 indicating that they express anthrax toxin 
receptors on their surface. However, the remaining 4 cell lines were resistant to 
PrAg/FP59 indicating the absence of anthrax toxin receptors on the cell surface and the 
subsequent inability to bind, activate and internalize the toxin.  
Moreover, we used the U0126 small molecule in order to investigate the cells 
response to MEK1/2 inhibition. None of the cell lines tested were sensitive to the 
inhibition of MAPK pathway via U0126. This result has further confirmed the lack of 
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sensitivity of our CRC panel of cell lines to MAPK pathway inactivation neither by LF- 
mediated inhibition nor by the U0126 MEK1/2 specific inhibitor. In addition, marginal 
cell cycle arrest was observed in some of the CRC cell lines tested indicating that, in 
addition to the lack of any significant cytotoxic effect, LF also lacks any cytostatic effect 
in CRC cells. This was surprising and differed from our experience in other tumor types 
such as melanoma and acute myeloid leukemia (AML) where a majority of cells were 
found to be dependent on the MAPK pathway for survival. Investigating the MAPK 
activation levels revealed a high levels of phosphorylated MEK 1/2, but surprisingly no 
active phosphorylated ERK 1/2. These results indicate that the MAPK pathway is not 
active, despite the presence of phospho-MEK1/2 since ERK1/2, the downstream effector 
of the MAPK pathway, is not active. Thus, it can be deduced that these cells are not 
dependent on the MAPK pathway for survival, even though they are Ras+ mutants. 
Hence, targeting the MAPK pathway would not sensitize the cells and would cause no 
LF-mediated cytotoxicity. This data is consistent with Abi-Habib et al. 2005, where the 
study showed that constitutive activation of the mitogen-activated protein kinase 
pathway associated with BRAF mutation status are actually sensitive to the anthrax 
lethal toxin, whereas ras+  mutants were resistant to the fusion toxin. None of  the CRC 
cell lines were significantly sensitive to the inhibition of PI3K pathway using the 
LY924002 PI3 kinase inhibitor. Also, none were sensitive to the co-treatment with both 
PrAg/LF and LY924002. Activation level of the PI3 kinase pathway was checked by 
investigating the phosphorylated levels of Akt component. No active phospho-Akt was 
detected on flow cytometry for any of the 8 cell lines tested, suggesting that CRC cell 
lines are also independent from PI3 kinase pathway for survival, and no synergistic 
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effect could be achieved by the inhibition of both the MAPK and PI3K pathway at the 
same time. 
In order to assess the possibility of targeting the uPA/uPAR system alone, we 
tested the sensitivity of CRC cells to PrAgU2/FP59, a urokinase activated, MAPK-
independent version of the toxin. PrAgU2/FP59 gets activated only in cells expressing 
uPA and leads to the translocation of FP59 into the cytosol where the latter acts by the 
inhibition of protein synthesis resulting in cell death. The vast majority of cell lines 
showed sensitivity to PrAgU2/FP59. Moreover, we determined the uPAR expression 
level on all 8 cell lines by uPAR cell surface staining on flow cytometry. Most of the 
cell lines were positive for uPAR expression suggesting a strong correlation between 
sensitivity to PrAgU2/FP59 and uPAR expression. These results indicate the possibility 
for targeting this protease system in CRC, besides considering the uPAR expression as a 
marker for sensitivity to the uPA/uPAR system targeting.  
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